We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Amylyx Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for Relyvrio to treat adults with amyotrophic lateral sclerosis (ALS). ALS, also known as Lou Gehrig’s
Sanofi and Regeneron Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved their Dupixent (dupilumab) to treat prurigo nodularis. Prurigo nodularis is an inflammatory skin
US-based cell therapy company Arsenal Biosciences (ArsenalBio) and Roche’s subsidiary Genentech have entered into a multi-year collaboration to identify T-Cell therapies for oncology. The collaboration will deploy ArsenalBio’s
US-based biopharmaceutical company Emergent BioSolutions has completed the acquisition of exclusive global rights to Tembexa (brincidofovir) from Chimerix. Tembexa is an oral antiviral approved by the US Food
AstraZeneca has received the European Commission (EC) approval for Ultomiris (ravulizumab) to treat a type of generalised myasthenia gravis (gMG) in adults. Ultomiris is a humanised monoclonal antibody
GSK has signed an exclusive licence agreement with Spero Therapeutics for the latter’s tebipenem pivoxil hydrobromide (tebipenem HBr). Tebipenem HBr is a late-stage, oral carbapenem antibiotic intended to
Eli Lilly and Company (Lilly) has received the US Food and Drug Administration (FDA) approval for Retevmo (selpercatinib) to treat a type of metastatic solid tumours in adult
Rocket Pharmaceuticals has agreed to acquire cardiovascular therapies company Renovacor in an all-stock transaction valued at around $2.60 per share, or a total of $53m. Under the terms
Roche has secured the European Commission (EC) approval for Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME). Vabysmo
Switzerland’s Competition Commission (COMCO) has launched an investigation on Novartis over the potential misuse of a patent in the field of dermatology treatments. As part of the investigation,